Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2015 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the Oppenheimer 26th Annual Healthcare Conference

ROCKVILLE, Md., Dec. 02, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
November 07, 2015 12:15 ET | Source: MacroGenics, Inc.

Data from MacroGenics’ Ongoing Phase 1 Study of Enoblituzumab (MGA271) Presented at 30th Annual SITC Meeting 2015

Anti-B7-H3 antibody is well-tolerated Single-agent, anti-tumor activity observed across several tumor typesInitial evidence of T-cell immunomodulatory role ROCKVILLE, Md., Nov. 07, 2015 ...
November 05, 2015 16:30 ET | Source: MacroGenics, Inc.

Publication in PLOS Pathogens Shows the Potential of DART® Molecules for HIV Reservoir Elimination Strategy

Second paper published demonstrating DART molecule potential against HIVData support HIV research contract recently awarded to MacroGenics by NIAID ...
November 04, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results

Bi-specific antibody leadership – fifth DART® molecule (MGD009) enters clinical testingB7-H3 franchise advances – Encouraging initial clinical results from ongoing enoblituzumab (MGA271) Phase 1...
November 04, 2015 07:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., Nov. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
October 28, 2015 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Third Quarter 2015 Financial Results Conference Call

Rockville, MD, Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 4, 2015, the Company will release its financial results for the...
October 28, 2015 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Regains European and Other Regional Rights to Enoblituzumab

Server does not exercise option to license rights for enoblituzumab in its specified territoriesMacroGenics advances enoblituzumab and pursues integrated B7-H3 franchise strategy Rockville, MD,...
October 22, 2015 07:30 ET | Source: MacroGenics, Inc.

MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer

ROCKVILLE, MD and KENILWORTH, NJ , Oct. 22, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing...
October 13, 2015 12:04 ET | Source: MacroGenics, Inc.

MacroGenics Highlights Progress at 2015 R&D Day

Encouraging initial clinical results from ongoing enoblituzumab (MGA271) trialB7-H3 franchise extended — fifth DART® molecule (MGD009) in Phase 1Proprietary immune checkpoint PD-1 x LAG-3 DART...
October 06, 2015 07:30 ET | Source: MacroGenics, Inc.

MacroGenics to Host 2015 R&D Day

ROCKVILLE, Md., Oct. 06, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...